Literature DB >> 23275229

Successful treatment of eltrombopag-resistant refractory immune thrombocytopenia with romiplostim.

Tomonori Nakazato, Chisako Ito, Ai Mihara, Yoshinobu Aisa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23275229     DOI： 10.1007/s12185-012-1253-0

Source DB:  PubMed          Journal:  Int J Hematol        ISSN： 0925-5710            Impact factor:   2.490


× No keyword cloud information.
  9 in total

1.  AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl.

Authors:  Virginia C Broudy; Nancy L Lin
Journal:  Cytokine       Date:  2004-01-21       Impact factor: 3.861

Review 2.  Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications.

Authors:  Kiarash Kojouri; Sara K Vesely; Deirdra R Terrell; James N George
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

3.  Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.

Authors:  Yukari Shirasugi; Kiyoshi Ando; Koji Miyazaki; Yoshiaki Tomiyama; Shinichiro Okamoto; Mineo Kurokawa; Keita Kirito; Yuji Yonemura; Shinichiro Mori; Kensuke Usuki; Koji Iwato; Satoshi Hashino; Helen Wei; Richard Lizambri
Journal:  Int J Hematol       Date:  2011-06-25       Impact factor: 2.490

4.  Romiplostim or standard of care in patients with immune thrombocytopenia.

Authors:  David J Kuter; Mathias Rummel; Ralph Boccia; B Gail Macik; Ingrid Pabinger; Dominik Selleslag; Francesco Rodeghiero; Beng H Chong; Xuena Wang; Dietmar P Berger
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

5.  Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial.

Authors:  James B Bussel; Drew Provan; Tahir Shamsi; Gregory Cheng; Bethan Psaila; Lidia Kovaleva; Abdulgabar Salama; Julian M Jenkins; Debasish Roychowdhury; Bhabita Mayer; Nicole Stone; Michael Arning
Journal:  Lancet       Date:  2009-02-21       Impact factor: 79.321

6.  Impaired platelet responses to thrombin and collagen in AKT-1-deficient mice.

Authors:  Juhua Chen; Sarmishtha De; Derek S Damron; William S Chen; Nissim Hay; Tatiana V Byzova
Journal:  Blood       Date:  2004-04-22       Impact factor: 22.113

Review 7.  The pathogenesis of chronic immune thrombocytopenic purpura.

Authors:  Robert McMillan
Journal:  Semin Hematol       Date:  2007-10       Impact factor: 3.851

8.  Thrombopoietin receptor agonists in refractory immune thrombocytopenia: differential responses to eltrombopag and romiplostim: a case report and possible explanations.

Authors:  T Aoki; Y Harada; E Matsubara; T Suzuki; T Oyama; M Kasai; T Uchida; M Ogura
Journal:  J Clin Pharm Ther       Date:  2012-05-14       Impact factor: 2.512

9.  Reduced corticosteroid use in adult patients with primary immune thrombocytopenia receiving romiplostim.

Authors:  Marc Michel; Peter A W te Boekhorst; Ann Janssens; Ingrid Pabinger-Fasching; Miguel A Sanz; Kun Nie; Georg Kreuzbauer
Journal:  Hematology       Date:  2011-09       Impact factor: 2.269
  9 in total
  2 in total

1.  Bidirectional inefficacy or intolerability of thrombopoietin receptor agonists: new data and a concise review.

Authors:  Fabian Depré; Nasra Aboud; Beate Mayer; Abdulgabar Salama
Journal:  Blood Transfus       Date:  2017-01-25       Impact factor: 3.443

Review 2.  The pharmacology and clinical application of thrombopoietin receptor agonists.

Authors:  Caizheng Li; Li Zheng
Journal:  Int J Hematol       Date:  2014-09-18       Impact factor: 2.490
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.